Clinical trial • Phase III • Gastroenterology
duvakitug for Healthy volunteers
Phase III trial of duvakitug for Healthy volunteers. 50 participants.
Overview
- Trial Therapeutic Area
- Gastroenterology
- Trial Disease
- Healthy volunteers
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 26-01-2026
- First CTIS Authorization Date
- 17-03-2026
Trial design
Phase III trial across 1 site in Germany.
- Target Sample Size
- 50
Eligibility
Recruits 50 Vulnerable population selected; no details on consent or assent handling available in source..
- Vulnerable Population
- Vulnerable population selected; no details on consent or assent handling available in source.
Recruitment
- Planned Sample Size
- 50
- Recruitment Window Months
- 2
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 50
Germany
- Earliest CTIS Part Ii Submission Date
- 03-03-2026
- Latest Decision Or Authorization Date
- 22-04-2026
- Processing Time Days
- 50
- Number Of Sites
- 1
- Number Of Participants
- 50
Sites
- Site Name
- Klinikum Westend Haus 31, Spandauer Damm 130, Charlottenburg
- Department Name
- Parexel – Early Phase Clinical Unit Berlin
- Contact Person Name
- Dirk Palla
- Contact Person Email
- dirk.palla@parexel.com
Sponsor
Primary sponsor
- Full Name
- Sanofi-Aventis Recherche & Developpement
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- France
Contract research organisations
- Name
- PAREXEL International GmbH
- Responsibilities
- Listed as site/operational contact in trialSites (contact and site management)
Investigational products
- Investigational Product Name
- duvakitug
Related trials
Other published trials that may interest you.